2X1.F · ABIVAX Société Anonyme
-
-
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | FR0012333284 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 332M |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 1.56 |
| Dividend Yield | None |
ABOUT
ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults and Phase 2b clinical trial of obefazimod in patients with Crohn's disease. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Learn More